抗冠状病毒药物“瑞德西韦”在中国的入院情况观察

IF 0.2 4区生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Law Report Pub Date : 2021-10-01 DOI:10.1089/blr.2021.29248.nl

Na Li, Xiang Yu

引用次数: 1

摘要

2020年初，中国爆发了新型冠状病毒肺炎。为了找到某种治疗方法，中国将注意力转向了吉利德生产的Remdesivir。在最初的阶段，Chi…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China

A novel coronavirus pneumonia broke out in early 2020 in China. In order to find a certain cure, China has turned its attention to Remdesivir, which is produced by Gilead. At the initial stage, Chi...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biotechnology Law Report 工程技术-生物工程与应用微生物

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The leading authoritative journal since 1982 devoted to the evolving body of law and government regulation concerning biotechnology, particularly in the industries in which new products from these technologies are developing the most rapidly: pharmaceuticals, chemicals, agriculture, food processing, energy, mineral recovery, and waste treatment. All legal aspects are rapidly reported, and critical and often hard-to-obtain documents are reproduced.